Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by fredgoodwinsonon Feb 15, 2022 8:19am
617 Views
Post# 34429161

RE:RE:RE:RE:Immunity bio doing well

RE:RE:RE:RE:Immunity bio doing well

Immunity Bio`s results are impressive but treatment looks to involve 2 x series of 6 instillations (including BCG) plus 3-year maintenance? In contrast and where TLT could really shine is through the reduction of an overwhelming and increasing workload in Public Health and beyond.

 

Imagine only 2 x outpatient treatments (six months apart) for refractory NMIBC? - or (thanks for the heads up Dawg) those given a diagnosis of later stage lung cancer booked in for a jab and an x-ray (with or without adjuvants)?

 

It is injectable Rutherrin (we are told here currently under development) that will take TLT to the next level with such treatments - the sooner it arrives the better for all.

 
<< Previous
Bullboard Posts
Next >>